Latest Clinical Trials
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Beat AML, LLC NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies M.D. Anderson Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine Groupe Francophone des Myelodysplasies NA COMPLETED
(Sep 1, 2026)
PHASE1, PHASE2 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation M.D. Anderson Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE2 Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Jennifer Saultz NA RECRUITING
(Sep 1, 2026)
PHASE1 Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML GWT-TUD GmbH NA COMPLETED
(Sep 1, 2026)
PHASE2 Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Seagen, a wholly owned subsidiary of Pfizer NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study of BGB-11417 in Participants With Myeloid Malignancies BeOne Medicines NA RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Alliance for Clinical Trials in Oncology NA RECRUITING
(Sep 1, 2026)
PHASE2 Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. Novartis Pharmaceuticals NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia Astellas Pharma Global Development, Inc. NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML Guangzhou Lupeng Pharmaceutical Company LTD. NA RECRUITING
(Sep 1, 2026)
PHASE1 A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia St. Jude Children's Research Hospital NA RECRUITING
(Sep 1, 2026)
PHASE2 A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML Stichting Hemato-Oncologie voor Volwassenen Nederland NA RECRUITING
(Sep 1, 2026)
PHASE2 Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients The Second Affiliated Hospital of Kunming Medical University NA COMPLETED
(Sep 1, 2026)
PHASE3 A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias M.D. Anderson Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE1 Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation Institut de Recherches Internationales Servier NA RECRUITING
(Sep 1, 2026)
PHASE3 Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML OHSU Knight Cancer Institute NA RECRUITING
(Sep 1, 2026)
PHASE2 A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm M.D. Anderson Cancer Center NA WITHDRAWN
(Sep 1, 2026)
PHASE2 A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) M.D. Anderson Cancer Center NA RECRUITING
(Sep 1, 2026)
PHASE1 Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias NA ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia Sichuan Baili Pharmaceutical Co., Ltd. NA RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax Timothy Pardee NA RECRUITING
(Sep 1, 2026)
PHASE2 Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML UNC Lineberger Comprehensive Cancer Center NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy Ipsen NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE2, PHASE3 Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN Virginia Commonwealth University NA RECRUITING
(Sep 1, 2026)
PHASE2 Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Guangdong Second Provincial General Hospital NA ENROLLING BY INVITATION
(Sep 1, 2026)
PHASE2 Hydrochloroquinine & Decitabine With Venetoclax in AML Rutgers, The State University of New Jersey NA NOT YET RECRUITING
(Sep 1, 2026)
PHASE1 Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma National Cancer Institute (NCI) NA SUSPENDED
(Aug 24, 2026)
PHASE1 Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome M.D. Anderson Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE2 IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome Groupe Francophone des Myelodysplasies NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome Groupe Francophone des Myelodysplasies NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT University of Birmingham NA COMPLETED
(Aug 1, 2026)
PHASE3 A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy Takeda NA COMPLETED
(Aug 1, 2026)
PHASE2 A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome Taiho Pharmaceutical Co., Ltd. NA RECRUITING
(Aug 1, 2026)
PHASE1 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) PedAL BCU, LLC NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Janssen Research & Development, LLC NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE2 Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE2 Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes Groupe Francophone des Myelodysplasies NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia Therapeutic Advances in Childhood Leukemia Consortium NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML Technische Universität Dresden NA RECRUITING
(Aug 1, 2026)
PHASE2 Pacritinib in CMML Douglas Tremblay NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Cladribine Venetoclax in Monocytic AML University of Colorado, Denver NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) National Cancer Institute (NCI) NA RECRUITING
(Aug 1, 2026)
PHASE2 Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML The First Affiliated Hospital of Soochow University NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy Stemline Therapeutics, Inc. NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML National Cancer Institute (NCI) NA SUSPENDED
(Aug 1, 2026)
PHASE1 Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Uma Borate NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML Stichting Hemato-Oncologie voor Volwassenen Nederland NA RECRUITING
(Aug 1, 2026)
PHASE3 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Janssen Research & Development, LLC NA RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia Memorial Sloan Kettering Cancer Center NA WITHDRAWN
(Aug 1, 2026)
PHASE2 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML Kura Oncology, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE3 Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms University of Washington NA RECRUITING
(Aug 1, 2026)
PHASE2 Pilot Study of Reduced Venetoclax Exposure Northwell Health NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) Kittika Poonsombudlert NA RECRUITING
(Aug 1, 2026)
PHASE1 Pacritinib With Aza for Upfront Myelodysplastic Syndrome Thomas Jefferson University NA WITHDRAWN
(Aug 1, 2026)
PHASE1, PHASE2 FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Fred Hutchinson Cancer Center NA RECRUITING
(Aug 1, 2026)
PHASE1 A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations M.D. Anderson Cancer Center NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia Florian Kuchenbauer NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Chaser Therapeutics, Inc. NA RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML Shanghai Jiao Tong University School of Medicine NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia BeOne Medicines NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(Aug 1, 2026)
PHASE1 Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer Celgene NA TERMINATED
(Jul 1, 2026)
PHASE2 Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia University of Colorado, Denver NA COMPLETED
(Jul 1, 2026)
PHASE2 Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma H. Lee Moffitt Cancer Center and Research Institute NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Johns Hopkins All Children's Hospital NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies National Cancer Institute (NCI) NA COMPLETED
(Jul 1, 2026)
PHASE1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations Eli Lilly and Company NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms University Health Network, Toronto NA RECRUITING
(Jul 1, 2026)
PHASE2 Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia Jonathan Brammer NA ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents Joshua Zeidner NA RECRUITING
(Jul 1, 2026)
PHASE2 Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia St. Jude Children's Research Hospital NA RECRUITING
(Jul 1, 2026)
PHASE1 Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant City of Hope Medical Center NA RECRUITING
(Jul 1, 2026)
PHASE1 A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia Memorial Sloan Kettering Cancer Center NA RECRUITING
(Jul 1, 2026)
PHASE2 Study of SA+X in the Treatment of Newly Diagnosed AML Ruijin Hospital NA RECRUITING
(Jul 1, 2026)
PHASE2 Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation OHSU Knight Cancer Institute NA RECRUITING
(Jul 1, 2026)
PHASE1 Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Roswell Park Cancer Institute NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma City of Hope Medical Center NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 New Genotype-guided Treatment in Newly Diagnosed PTCL Ruijin Hospital NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML The Second Affiliated Hospital of Kunming Medical University NA RECRUITING
(Jul 1, 2026)
PHASE3 A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients Cullinan Therapeutics Inc. NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE1 A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia Maxinovel Pty., Ltd. NA RECRUITING
(Jul 1, 2026)
PHASE2 The Efficacy of CAPCT in Patients With PTCL The First Affiliated Hospital with Nanjing Medical University NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Astellas Pharma Global Development, Inc. NA COMPLETED
(Jun 1, 2026)
PHASE3 SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Dana-Farber Cancer Institute NA RECRUITING
(Jun 1, 2026)
PHASE1 Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation Institut de Recherches Internationales Servier NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia M.D. Anderson Cancer Center NA RECRUITING
(Jun 1, 2026)
PHASE2 Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma Celgene NA COMPLETED
(Jun 1, 2026)
PHASE3 Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies CellCentric Ltd. NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy PETHEMA Foundation NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) AbbVie NA TERMINATED
(Jun 1, 2026)
PHASE3 Study to Evaluate the Safety and Tolerability of EP0042 Ellipses Pharma NA RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer University of Illinois at Chicago NA RECRUITING
(Jun 1, 2026)
PHASE2 CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed City of Hope Medical Center NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts M.D. Anderson Cancer Center NA RECRUITING
(Jun 1, 2026)
PHASE2 IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Alice Mims NA RECRUITING
(Jun 1, 2026)
PHASE2 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) National Cancer Institute (NCI) NA RECRUITING
(Jun 1, 2026)
PHASE2 Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome Molecular Partners AG NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) M.D. Anderson Cancer Center NA RECRUITING
(Jun 1, 2026)
PHASE1 Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) Antonio M Jimenez Jimenez NA TERMINATED
(Jun 1, 2026)
PHASE1 Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent University of California, Davis NA RECRUITING
(Jun 1, 2026)
PHASE2 VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. Hematology department of the 920th hospital NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML Dongguan People's Hospital NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations Shen yang NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE2 VA Consolidation in Intermediate-Risk AML The First Affiliated Hospital of Soochow University NA RECRUITING
(Jun 1, 2026)
PHASE2 Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(Jun 1, 2026)
PHASE3 A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT Liping Dou NA ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy AbbVie NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Jacqueline Garcia, MD NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia OncoVerity, Inc. NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome AbbVie NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old PETHEMA Foundation NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia Institut de Recherches Internationales Servier NA COMPLETED
(May 1, 2026)
PHASE1, PHASE2 Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Massachusetts General Hospital NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML Sunshine Lake Pharma Co., Ltd. NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma M.D. Anderson Cancer Center NA RECRUITING
(May 1, 2026)
PHASE2 Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Uma Borate NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. Servier Affaires Médicales NA RECRUITING
(May 1, 2026)
PHASE3 A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS Apollo Therapeutics Ltd NA RECRUITING
(May 1, 2026)
PHASE1 A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy OncoVerity, Inc. NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia M.D. Anderson Cancer Center NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation Institute of Hematology & Blood Diseases Hospital, China NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML Institute of Hematology & Blood Diseases Hospital, China NA RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML Institute of Hematology & Blood Diseases Hospital, China NA RECRUITING
(May 1, 2026)
PHASE2 HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML Institute of Hematology & Blood Diseases Hospital, China NA ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS University of Virginia NA RECRUITING
(May 1, 2026)
PHASE1 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors Mohammed Milhem NA RECRUITING
(May 1, 2026)
PHASE1 tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy Shirley Ryan AbilityLab NA RECRUITING
(May 1, 2026)
PHASE2 Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy Shirley Ryan AbilityLab NA RECRUITING
(May 1, 2026)
PHASE2 A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia The First Affiliated Hospital of Soochow University NA NOT YET RECRUITING
(May 1, 2026)
PHASE2 VABu Conditioning in Elderly AML HSCT The First Affiliated Hospital of Soochow University NA RECRUITING
(May 1, 2026)
PHASE2, PHASE3 Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy First Affiliated Hospital of Zhejiang University NA ENROLLING BY INVITATION
(May 1, 2026)
PHASE2, PHASE3 Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy First Affiliated Hospital of Zhejiang University NA ENROLLING BY INVITATION
(May 1, 2026)
PHASE2, PHASE3 Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia University Hospital, Bordeaux NA NOT YET RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma M.D. Anderson Cancer Center NA COMPLETED
(Apr 1, 2026)
PHASE2 A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) BioLite, Inc. NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia St. Jude Children's Research Hospital NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML University of Colorado, Denver NA COMPLETED
(Apr 1, 2026)
PHASE2 Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL The Lymphoma Academic Research Organisation NA COMPLETED
(Apr 1, 2026)
PHASE3 Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm M.D. Anderson Cancer Center NA RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) Taiho Oncology, Inc. NA RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia M.D. Anderson Cancer Center NA TERMINATED
(Apr 1, 2026)
PHASE1, PHASE2 Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma National Cancer Institute (NCI) NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients University of Florence NA COMPLETED
(Apr 1, 2026)
PHASE2 A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. Novartis Pharmaceuticals NA COMPLETED
(Apr 1, 2026)
PHASE1 Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma The First Affiliated Hospital of Soochow University NA RECRUITING
(Apr 1, 2026)
PHASE2 An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission Bristol-Myers Squibb NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies Faron Pharmaceuticals Ltd NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML Sunshine Lake Pharma Co., Ltd. NA RECRUITING
(Apr 1, 2026)
PHASE3 Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy University of Leipzig NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Bristol-Myers Squibb NA RECRUITING
(Apr 1, 2026)
PHASE1 Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia Shanghai Jiao Tong University School of Medicine NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy Justin Watts, MD NA RECRUITING
(Apr 1, 2026)
PHASE2 Imetelstat Combinations in Relapsed AML Douglas Tremblay NA RECRUITING
(Apr 1, 2026)
PHASE1 VAH vs VA in Newly Diagnosed Elderly AML Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL Ruijin Hospital NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL). Guangdong Second Provincial General Hospital NA ENROLLING BY INVITATION
(Apr 1, 2026)
PHASE2 Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS The First Affiliated Hospital of Soochow University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS The First Affiliated Hospital of Soochow University NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE2 Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Ruijin Hospital NA NOT YET RECRUITING
(Apr 1, 2026)
PHASE3 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Celgene NA COMPLETED
(Mar 1, 2026)
PHASE2 Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Curis, Inc. NA SUSPENDED
(Mar 1, 2026)
PHASE1, PHASE2 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML Sellas Life Sciences Group NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) Sumitomo Pharma America, Inc. NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Venetoclax Basket Trial for High Risk Hematologic Malignancies Andrew E. Place, MD NA RECRUITING
(Mar 1, 2026)
PHASE1 Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients The First Affiliated Hospital of Soochow University NA RECRUITING
(Mar 1, 2026)
PHASE2 Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients The First Affiliated Hospital of Soochow University NA ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome Medical College of Wisconsin NA RECRUITING
(Mar 1, 2026)
PHASE1 A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) M.D. Anderson Cancer Center NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients Institut Paoli-Calmettes NA RECRUITING
(Mar 1, 2026)
PHASE2 A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients Chinese PLA General Hospital NA RECRUITING
(Mar 1, 2026)
PHASE2 Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker The Methodist Hospital Research Institute NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Institute of Hematology & Blood Diseases Hospital, China NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. French Innovative Leukemia Organisation NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE2 Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML The First Affiliated Hospital of Soochow University NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE3 Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia Shanghai Jiao Tong University School of Medicine NA NOT YET RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML M.D. Anderson Cancer Center NA RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia Chinese PLA General Hospital NA RECRUITING
(Mar 1, 2026)
PHASE2 VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial Beijing 302 Hospital NA RECRUITING
(Mar 1, 2026)
PHASE2 Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia Chinese PLA General Hospital NA RECRUITING
(Mar 1, 2026)
PHASE3 
